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Introduction 
Obesity is one of the most important global health problems. The World Health 
Organization (WHO) estimated that in 2016, around 13% of adults worldwide were 
obese, and 18% of children and adolescents were overweight or obese [1]. The 
global prevalence of obesity tripled in epidemical proportions between the years 
1975 and 2016 [1, 2, 3]. The global burden of obesity encompasses a broad 
spectrum of pathology that confers a substantial healthcare economic impact [1, 
4].   
 
Although changes in lifestyle (including diet and activity) have contributed towards 
increases in body weight [1, 5], genetic effects are also important, Body Mass 
Index (BMI) having a heritability of up to 70% [3, 6, 7, 8, 9].  Genome-wide 
association studies (GWAS), which attempt to identify genetic associations of 
certain traits or conditions by testing for a large number of common genetic 
variants (single nucleotide polymorphisms) in both those affected and control 
groups, and then comparing the relative frequencies with which the genetic 
variants appear [9], have identified more than 90 genetic loci which are associated 
with BMI [3]. Nevertheless, these identified genetic loci only account for a small 
proportion (around 2.7%) of the population-based variation in BMI [3, 9]. 
Furthermore, underlying mechanisms linking gene variants with BMI are 
incompletely understood [3]. It is possible that epigenetic effects may account for 
some of the heritability of BMI [9]. It is also possible that some genetic loci with 
very small effects on BMI have not been identified from the GWAS that have been 
reported to date and require much larger population-based studies to detect. In 
addition, it is conceivable that non-mutational genetic differences, such as copy 
number variation (CNV), influence the metabolic phenotype and may account for 
some of the missing heritability [9].  
 
CNV refers to the phenomenon whereby genes, or parts of genes, are replicated in 
sequence or deleted within a chromosome [9]. Detection of single nucleotide 
polymorphisms (SNP) mutations in GWAS [9] may identify some CNVs due to 
‘tagging’ to surrounding SNPs [10, 11], but more complex multi-allelic CNVs are 
less readily identified through GWAS [10, 12]. One region of particular interest that 
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displays such multi-allelic complexity is the genetic sequence coding for the 
amylase enzymes [10]. In humans, the amylase enzyme occurs in two distinct 
forms: i) salivary (produced by the salivary glands), and; ii) pancreatic (produced 
by the exocrine pancreas) [13, 14].  These enzymes play a key role in the digestion 
of starch.  Salivary amylase, the most abundant protein in saliva [15, 16], 
facilitates hydrolysis of -1,4 glycosidic bonds within the oral cavity [15], 
producing maltose, isomaltose, oligosaccharides and a small amount of glucose 
[13, 15, 17].  Further down the alimentary tract within the ileum, pancreatic 
amylase continues this process of hydrolysis [15, 18]. Resulting products are broken 
down into absorbable free glucose by enzymes within the brush border of the 
ileum [18].  Small amounts of amylase are also produced by the liver [13, 19-21], 
nervous system, mammary tissue, uterus and testes [21].   
 
In humans, salivary amylase is encoded by three specific genes: AMY1A, AMY1B and 
AMY1C. Conversely, human pancreatic amylase is encoded by two genes: AMY2A 
and AMY2B [10, 22].  Together with a pseudogene, AMYP1, these genes are all 
located within a single section of chromosome 1, at the locus 1p21.1 [22]. The 
three AMY1 genes are very similar [10, 22], and may be grouped together and 
collectively referred to as ‘AMY1’, while the two pancreatic genes may also be 
collectively termed ‘AMY2’ [10]. It is well established that human salivary and 
pancreatic amylase genes manifest remarkable CNV [22-25]. Within an individual 
genome, there may be between 1-27 copies of AMY1 [21], 0-8 copies of AMY2A 
[26, 27] and 2-6 copies of AMY2B [27]. However, the potential implications of 
amylase gene CNV for BMI and metabolic function have only become apparent in 
recent years. 
 
In this review, we explore in detail the evidence within the current literature that 
confirms or refutes association between CNV within the human amylase genes and 
BMI and other metabolic markers. Possible underlying mechanisms to explain such 
associations are also explored. Finally, the clinical implications for such an 
association between amylase gene CNV and BMI and metabolic health is discussed, 
including suggestions for future directions in this fascinating and emergent field. 
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Evolutionary drive for CNV within AMY1 
Before exploring the association between CNV within AMY1 and BMI, and the 
possible mechanisms involved, let’s take a step back and consider why there is so 
much variation in copy number within AMY1 within humans, and what has driven 
such variation. In short, why is there not just one AMY1 copy in the human genome 
(as with most other genes), instead of many? 
 
A clue originates from the observation of a positive correlation between CNV 
within AMY1 and the concentration and activity of salivary amylase in humans: 
increased copies of AMY1 presumably result in increased production and activity of 
salivary amylase, thereby facilitating initiation of amylase digestion within the 
saliva [14, 15, 18, 21, 25, 28-31]. Although pancreatic amylase accounts for most 
of digestion of starch within the diet, the role of salivary amylase in starch 
digestion should not be under-estimated [32]. A sizable proportion of starch 
hydrolysis occurs within the oral cavity during mastication of food [32, 33]. 
Furthermore, swallowing starch-rich foods before mastication, and thus reduced 
mixing with saliva, leads to a lower post-prandial blood glucose concentration [32, 
34], thereby implying reduced effectiveness of starch digestion. 
 
It has been hypothesised that CNV within AMY1 represents an evolutionary 
adaptation to increasing levels of starch in the human diet. There is some evidence 
to support such a hypothesis.  First of all, studies have shown that humans and 
rodents both obtained the expression of salivary amylase independently by a 
retroviral insertion into the amylase gene region; the fact that it has persisted in 
both evolutionary lines suggests that the expression of salivary amylase confers a 
selective advantage [14, 35, 36]. Next, obligate carnivores do not produce salivary 
amylase [14, 37], whereas animals which feed on starch-rich plant matter, such as 
fruits and seeds, display salivary amylase activity [14]. Although domesticated dogs 
do not produce salivary amylase [14, 38, 39, 40], they do display CNV of AMY2B, 
which is correlated with serum amylase activity [40]. Wolves, on the other hand, 
follow a carnivorous diet and do not exhibit AMY2B CNV [39]. It has therefore been 
suggested that dogs acquired AMY2B CNV in order to adapt to a starch-rich diet 
[14, 39, 40], which represented an important step in their domestication [39]. 
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Furthermore, when compared to other primates which consume lower amounts of 
starch, humans appear to possess higher AMY1 copy number [21, 25, 41] and 
express higher levels of salivary amylase [25]: for example, chimpanzees do not 
demonstrate AMY1 CNV at all, possessing only one copy per chromosome [25, 42], 
and the quantity of salivary amylase produced by humans is around 6-8 times 
greater [25, 43]. Although gorillas and bonobos do exhibit CNV [21, 25, 38], 
humans have a higher copy number than the former [38] and the latter’s AMY1 
copies may not be functional [25]. This difference in CNV largely reflects their 
respective diets: while gorillas may have a high starch intake [44], chimpanzees 
consume very little compared to the majority of human populations [25, 45]. The 
fact that humans seem to have higher AMY1 copy numbers than other nonhuman 
primates, and also have a higher dietary starch intake, supports the idea that 
AMY1 CNV, and the increased salivary amylase levels that it engenders, represents 
an evolutionary adaptation to higher starch consumption. However, it must be 
acknowledged that AMY1 and AMY2 CNV have not yet been systematically studied 
in these nonhuman primates in any detail, and existing studies have used small 
sample sizes [21]. In addition, the correlation between AMY1 copy number and 
salivary amylase activity has yet to be studied in any species other than humans 
[21]. This makes it difficult to derive any definitive conclusion from these findings.  
 
Nevertheless, among humans alone, Perry and colleagues found that populations 
with a diet traditionally high in starch have higher copy numbers of the AMY1 gene 
compared with those populations that consume less starch [25], which lends 
further weight to the hypothesis described above. But if AMY1 CNV does represent 
an adaptation to increased levels of starch in the human diet, at what point in 
evolutionary history did it occur, and why did it occur at that time? It has been 
suggested that it accompanied the development of agriculture [21, 22, 25, 32, 46, 
47], which occurred around 10,000 BC, but it is unlikely that such a major change 
in the genome could have occurred in such a short space of time. Furthermore, 
AMY1 CNV has been found in ancient hunter-gatherers, predating the introduction 
of agriculture [48, 49].  
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Hardy and colleagues proposed that AMY1 CNV may have occurred during the 
Middle Pleistocene era [30, 31], before humans diverged from Neanderthals, and 
was therefore present in the first Homo sapiens. From this era onwards, there was 
a significant growth in brain size in human ancestors [30, 31], which would have 
necessitated a greater supply of preformed glucose. The authors argued that the 
widespread introduction among hominins of cooking, together with the 
development of AMY1 copy numbers and the increased salivary amylase activity it 
generated, were responsible for this increased preformed glucose supply, and 
therefore made this neurological development possible [30, 31]. Indeed, once 
cooking was developed, starch digestion would have become the rate-limiting step 
in its utilisation [30]. This hypothesis suggests that the development of AMY1 CNV 
‘coevolved’ with the development of cooking, and provided a selective advantage 
due to its provision of increased glucose to the developing brain. 
 
However, in analyses performed on a Neandertal and a Denisovan (a member of 
another distinct archaic hominin population), it was estimated that they had only 
one AMY1 copy per chromosome and therefore, like the chimpanzee, did not 
display CNV [42]; this could indicate that the development of AMY1 CNV occurred 
in human ancestors after their evolutionary split from the Neandertals and 
Denisovans around 550-590,000 years ago [42]. A recent study which analysed 
genetic variation around the amylase gene locus in a global set of human 
populations reinforced this finding [31]. The authors determined that AMY1 copy 
numbers developed in the late Middle Pleistocene period, after humans had 
diverged from Neanderthals and long after the development of cooking and the 
increase in hominin brain size had already taken place [21, 31]. 
 
Of course, the hypotheses described above are ultimately speculative. In the 
populations studied by Perry and colleagues [25], limited information on their 
prehistoric diets is available, and they did not use standard dietary intake 
assessment methods [21]. Their assertion that AMY1 copy number is higher in 
populations that have traditionally consumed a greater amount of dietary starch 
may not therefore be wholly accurate [21]. Furthermore, we cannot accurately 
identify the exact temporal origin of AMY1 CNV, nor when cooking was widely 
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adopted by human ancestors [30]. However, if the origin of AMY1 CNV predates the 
development of agriculture and postdates the widespread introduction of cooking, 
and may have been present in the first humans, it does not necessarily mean that 
it has conferred no selective advantage in modern human history [47]. It is still 
possible that high numbers of AMY1 copies were favoured in populations with 
starch-rich diets, and have been retained. This could at least partially explain why 
some present-day humans do not possess increased AMY1 copy numbers, as this 
may represent a secondary loss that arose with a change in diet that no longer 
favoured increased starch digestion [31]. Indeed, it has been shown that Northeast 
Siberian populations, who have traditionally followed a low-starch diet, have a 
high frequency of AMY2A deletion and associated low AMY1 copy number [31]. This 
hypothesis may also help to explain why there is such great AMY1 copy number 
heterogeneity in human populations. 
 
Ultimately, it will remain difficult to prove whether or not AMY1 copy number 
expansion conferred a specific evolutionary advantage, and when this occurred. 
Yet that does not make this phenomenon any less relevant. In the next sections, 
we examine the metabolic implications for individuals of amylase gene CNV. 
 
Association between CNV within AMY1 and BMI 
The link between CNV within human AMY1 and BMI was first described by Falchi 
and colleagues in 2014 [10]. Through a ‘gene-centric’ and quantitative PCR (qPCR) 
approach, a strong inverse association between CNV within AMY1 and BMI and fat 
mass was shown [10, 50]. This association was first identified in a single cohort, 
then replicated in >6,000 participants from a number of different cohorts, 
comprising both European and Singaporean Chinese ethnicities [10]. Each 
additional copy of the AMY1 gene reduced the risk of obesity 1.2-fold [10,27]. The 
risk of obesity in those with CNV<4 was 8-fold higher than in those with CNV>9 
[10].  Indeed, this link between AMY1 and BMI was stronger than that previously 
identified between obesity and FTO, the gene which has been found to have the 
greatest effect on obesity risk of any of those identified by GWAS [10, 27, 51]. In 
this study, however, no association between copy numbers of the AMY2 genes and 
BMI or fat mass was observed.  
9 
 
 
Consistent with data from Falchi and colleagues [10], other studies have also 
shown associations between CNV within human AMY1 (measured using qPCR) and 
BMI, obesity and insulin resistance [52], although results have been mixed.  In one 
study on Italian primary school children, although no overall association between 
CNV within AMY1 and BMI or waist circumference was demonstrated, such an 
association was present in boys alone [53]. Other authors, using qPCR to assess the 
relationship between AMY1 and BMI, failed to establish any correlation. Among 
these reports is a cross-sectional analysis of an adult South Korean population that 
showed no association between CNV within AMY1 and BMI, (although there was 
association with insulin resistance) [52].   
 
It should be noted that complex CNV is inherently difficult to measure [27, 54], 
especially for AMY1 (due to the high number of AMY1 copies and close proximity of 
the highly similar AMY1 and AMY2 genes) [22, 46]. Unfortunately, qPCR as a 
technique to measure CNV within AMY1 has inherent limitations [27, 55, 56].  More 
accurate techniques, including a combination of qPCR with ‘digital PCR’ (dPCR), 
‘droplet digital PCR’ (ddPCR), ‘sequence read depth techniques’ and ‘paralogue 
ratio tests (PRTs) and microsatellite measurements’, have shown that the 
arrangement of the amylase genes is not merely a copy number continuum [46], 
but categorized into separate haplotypes [22, 27, 46]. Indeed, 8 common 
haplotypes were shown to account for 98% of the combinations of AMY1, AMY2A 
and AMY2B copy numbers observed in a European cohort [27].  This is in contrast 
with data from Falchi and colleagues and other studies using qPCR that showed an 
approximate normal distribution of AMY1 copy number [10, 13, 22, 25].  
 
Furthermore, the copy numbers of AMY1 and AMY2A were shown to be significantly 
correlated in European populations by two studies using accurate CNV 
measurement techniques: the first used PRTs and microsatellite measurements 
[46], while the second used a novel method, ‘automatic modeling functionality for 
copy number estimation’, or ‘AMYCNE’, which uses whole genome sequencing data 
and appears to exhibit a similar level of accuracy to ddPCR [57]. The haplotype 
arrangements of AMY1 and AMY2A CNV are also correlated. Studies using these 
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accurate measurement techniques have shown that there is usually parity between 
the AMY1 and AMY2A copy numbers: in other words, if the copy number of AMY1 is 
odd, then the copy number of AMY2A is also odd, and vice versa [27, 57]. Moreover, 
an individual chromosome with an odd AMY1 copy number, will have one copy each 
of AMY2A and AMY2B, and will therefore not exhibit CNV in the latter two genes; 
on the other hand, those with an even AMY1 copy number, which is rarer, do 
exhibit CNV of the AMY2 genes [27, 46, 58]. This means that the copy numbers of 
AMY1 and AMY2 are dependent on each other. It is possible therefore that the 
association data outlined above may be influenced by specific haplotypes [56, 58], 
with odd or even haplotypes interacting with the copy numbers in different ways 
to determine gene expression [58]; or even by AMY2 copy number [46], rather than 
simply by copy number of AMY1. This insight has mechanistic implications. It is 
worth noting that one study which examined the relationship between AMY2 copy 
number and salivary amylase production and activity found no significant 
correlation between them [58], which suggests that AMY2 copy number has a 
limited effect on this enzyme. However, this does not necessary exclude a role for 
AMY2 in the association between CNV with amylase genes and body weight. Rather, 
it broadens potential mechanisms for this association from those involving solely 
salivary amylase to those that include pancreatic amylase too. Indeed, although 
we are not aware of any studies which have directly measured the production and 
activity of pancreatic amylase in the alimentary tract and compared it to AMY2 
copy number, it has been shown to be correlated with levels of pancreatic amylase 
in the serum [10,58], which indicates that AMY2 copy number influences secretion 
of this enzyme by the pancreas, just as a role for AMY1 copy number in 
determining salivary amylase secretion has previously been identified [14, 15, 18, 
21, 25, 28-31].  
 
The limitations of qPCR as a method of measuring CNV mean that the results of any 
study which has used it to measure AMY1 copy number are subject to potential 
inaccuracy, including those of Falchi and colleagues [27, 56].  It is, however, 
possible that these studies still identified a true relationship: for example, Falchi 
et al. reported that their measurements using qPCR were reproducible [10], and 
reproducible miscalibrated measurements could still have detected a true 
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association [46]; it has also been shown that qPCR measures could still generate 
the relative pattern of overall results as produced by more accurate methods [22].  
Nevertheless, for the reasons described above, their results must be interpreted 
with caution. 
As outlined above, other techniques which are more accurate than qPCR for 
measuring gene copy number are available. Consistent with data from Falchi and 
colleagues outlined above [10], employment of such techniques has identified 
further associations between CNV within AMY1 and obesity. In one study on 
Mexican children [59], which used dPCR, this association was apparently influenced 
by those participants with the highest AMY1 CNV [27, 59], a high AMY1 copy 
number being protective against obesity in this population [59]. No pre-dPCR 
enzyme digestion was performed on the DNA samples, which may have led to 
underestimation of AMY1 CNV and therefore affected the validity of the results of 
this study [22]. Nevertheless, further evidence to support an association between 
CNV within AMY1 comes from two studies which used the ddPCR technique, whose 
superior accuracy over qPCR has been validated [55]. The first, a study on Finnish 
participants who had a history of severe childhood obesity showed a significant 
inverse association between CNV within AMY1 and both BMI and percentage body 
fat in obese females [60]. The second conducted two large case-control studies on 
French middle-aged adults and children [61]. Overall, a higher CNV within AMY1 
was associated with reduced risk for obesity, this association being particularly 
marked in the child population [61]. It has been hypothesized that genetic factors 
have a greater effect on BMI in children and adolescents than in adults [61-63], 
stemming from differences in gene-environment interactions at different ages [61-
63]. Interactions between genes influencing BMI with environmental factors (diet 
and exercise primarily) are likely to be particularly strong during growth and 
development. This insight may explain the differences in association between CNV 
within AMY1 and BMI between the child and adult populations outlined above [61]. 
Consistent with this hypothesis, other studies have shown isolated associations 
between CNV within AMY1 and BMI in young people [53, 59, 61]. 
 
As with the qPCR technique, not all studies on the AMY1 CNV using the ddPCR 
technique have shown positive results, and there remains some controversy within 
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the field. In one study reported to have used the ddPCR technique, as well as read 
depth techniques [21, 27], to measure CNV in three cohorts (over 4,000 
participants), no association between CNV within either amylase gene (AMY1 and 
AMY2) and BMI [27, 56] was shown. Other studies on East Asian and Swedish 
cohorts, which used a novel method combining qPCR and dPCR, and ddPCR 
respectively, also showed no such association [22, 64]. 
 
What can we conclude from these studies? Although direct comparison between 
them is difficult due to different techniques and different populations studied, 
lack of overall uniformity and consistency among data from all reported studies in 
this field has resulted inevitably in some controversy regarding the veracity of the 
association between CNV within AMY1 and BMI. The findings of the first study to 
identify this association [10] have been contested due to the technical 
inaccuracies of qPCR techniques used to measure AMY1 copy number, and the 
findings of other studies which used similar techniques must inevitably also be 
questioned [52, 53]. Several high-powered studies which have used more accurate 
techniques failed to find any association at all, despite having more than adequate 
power to do so [22, 27, 64]. It is possible (indeed likely) that the many genetic and 
environmental factors known to influence BMI throughout life have a diluting 
effect on association between CNV within AMY1 and BMI. Nevertheless, a recent 
study which also had significant statistical power did find an overall association 
between AMY1 copy number and lower obesity risk which was stronger in children 
[61]. This finding was concordant with several other studies, albeit those with 
potential methodological inaccuracies [53, 59]. It appears that gene effects 
exerted during growth and development may have a particularly marked effect on 
the establishment of BMI, and this may well also be true of the association 
between AMY1 CNV and obesity. However, it is clear that further high-powered 
studies are required in order to support this hypothesis, and determine the nature 
of this relationship in all populations with greater precision. 
 
It should be emphasized that studies reported to date have focused primarily on 
associations. Such data provide little insight on causality or possible mechanisms. It 
seems reasonable to hypothesize, however, that differences in copy number of AMY1 
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have at least some effect on propensity for weight gain and development of obesity. 
On first glance, one may assume that such an association between CNV within AMY1 
and obesity is driven by enhanced breakdown of salivary starch and therefore 
increased absorption of sugar. It is perhaps surprising therefore, that the association 
data outlined above point in the opposite direction! It appears that low (rather than 
high) copy number of AMY1 (and by implication reduced amount of salivary amylase, 
and reduced breakdown of starch) is associated with increased risk for obesity. Such 
an association, which is perhaps contrary to expectation, demands a rational and 
plausible physiological explanation. To address this question, the role of AMY1 CNV 
on postprandial glucose control is explored in the next section.  
 
CNV within AMY1, salivary amylase and glucose homeostasis 
Differences in the efficiency of starch digestion have been hypothesized to explain 
the putative association between CNV within AMY1 and obesity outlined in the last 
section [59, 61]. Indeed, the relationship between CNV within AMY1 and metabolic 
state was initially explored regarding glucose homeostasis.  
 
Mandel and colleagues showed that high salivary amylase concentration and 
activity (in turn associated with higher CNV within AMY1) were associated with 
enhanced reduction in viscosity of starch (both in vitro and within the oral cavity 
in vivo), indicating that salivary amylase has an important effect on starch 
digestion even before food is swallowed. Furthermore, salivary amylase 
concentration and activity correlated directly and significantly with AMY1 CNV 
[15]. The hypothesis that enhanced oral breakdown of starch in individuals with 
increased levels of salivary amylase would in turn result in greater glycaemic load 
from a high-starch meal was refuted by ongoing research from the same group. 
Those individuals with higher salivary amylase levels in fact had significantly lower 
postprandial blood glucose responses to starch ingestion, and a more pronounced 
postprandial excursion of insulin within the first 9 minutes following the starch 
ingestion [32]. Insulin deficiency and resistance in the lower amylase group were 
eliminated given that both groups exhibited comparable blood glucose and insulin 
excursions following ingestion of a control glucose solution, absorption of which 
would not be expected to be influenced by the action of salivary amylase.  
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Given that blood glucose levels in both (high and low salivary amylase) groups did 
not start to rise until 15-minutes after starch ingestion, the implication is that the 
earlier observed rise in plasma insulin levels is ‘pre-absorptive’, and may therefore 
relate to ‘pre-absorptive’ or ‘cephalic phase’ insulin release (CPIR) [32]. CPIR 
usually occurs in anticipation of digestion just prior to or during food ingestion [32, 
65, 66], in tandem with secretion of gastric acid [32, 65, 67] and pancreatic 
enzymes [32, 65, 68].  Cephalic phase responses (the anticipatory phase of 
digestion) that include CPIR prime the body for efficient digestion and assimilation 
of ingested nutrients and may facilitate prevention of dysglycemia and 
dyslipidaemia [14]. CPIR is required for normal postprandial glucose tolerance [14, 
69] and mediated primarily by autonomic mechanisms triggered by oral sensory 
stimulation [69]. Absent CPIR results in higher postprandial glucose levels and 
impaired glucose tolerance in humans [32, 70].   
 
Although both groups showed CPIR following glucose ingestion, only the high 
amylase group demonstrated CPIR following starch ingestion [32]. One possible 
mechanism is that starch breakdown products in the high salivary amylase group 
are detected in the oral cavity and trigger CPIR [32]. Such a mechanism may 
implicate carbohydrate activation of lingual taste receptors to release (through 
autonomic signalling) incretin hormones such as glucagon-like peptide-1 (GLP-1) 
[32], gastric inhibitory polypeptide (GIP) [13], peptide YY and pancreatic amylase 
[71, 72]. Other products generated from starch breakdown in the mouth, such as 
glucose/maltose or short-chain oligosaccharides, may bind to lingual taste and 
polysaccharide receptors respectively, and activate CPIR even when conscious 
sweet taste perception does not occur [32]. It should be emphasized that the 
hypotheses outlined here remain speculative. However, the fast response of CPIR in 
high salivary amylase individuals implicates a likely autonomic response resulting 
in incretin effects. 
 
Data from other studies on the relationship between salivary amylase and 
postprandial glucose response to a starch-rich meal are variable. In one study, 
correlation between AMY1 CNV and salivary amylase activity and concentration 
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was shown. Consistent with data from Mandel and Breslin [32], increased salivary 
amylase activity correlated with less pronounced postprandial blood glucose 
excursions and increased insulin levels, although this relationship failed to reach 
significance [18]. A further study which examined glycaemic response following 
ingestion of white rice in Asian participants, failed to demonstrate any association 
between salivary amylase activity (or AMY1 CNV) and postprandial glycaemic 
response following a starch-rich meal [29]. Differences in starch preparations, 
power (based on numbers of participants) and timing of postprandial glucose and 
insulin measurements between studies may explain some of the apparent 
heterogeneity of data within the literature [18, 29, 33].   
 
In a study on mice, a novel metabolic pathway for monosaccharides involving taste 
receptor cells (independent of the type 1 taste receptors 2 and 3 (T1R2/T1R3) 
which detect sweet taste [73]), which comprises GLUT glucose transporters, 
sodium glucose cotransporter 1 (SGLT1) and ATP-gated K+ channels (KATP), was 
identified [14, 73].  Although salivary amylase in mice is not thought to generate 
sufficient glucose to activate these novel pathways, membrane-bound 
disaccharidase enzymes are expressed in taste receptor cells [14, 74]. Locally-
produced salivary amylase may generate high levels of oligosaccharides and 
disaccharides within the vicinity of taste receptors on the tongue, where 
disaccharidase enzyme activity produces monosaccharides that in turn may be 
detected by GLUT and SGLT1 transporters [14, 74]. Such a pathway may modulate 
CPIR in response to lingual sugar detection in mice [14, 75]. Although this pathway 
has not yet been identified in humans, it is conceivable that might be present. 
 
In humans, salivary amylase may also be implicated in stimulation of the CPIR 
response and improved glucose tolerance following starch ingestion. Starch 
breakdown products may be detected in the oral cavity, by either or both the T1R-
independent metabolic pathway and the polysaccharide receptor that can bind 
short-chain oligosaccharides [14, 32, 76]. CPIR triggered by elevated levels of 
salivary amylase may have provided an evolutionary advantage as starch 
consumption increased among human populations, thereby promoting AMY1 CNV 
expansion within the population [32]. Individuals with lower AMY1 CNV and 
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therefore low levels of salivary amylase, may be less well adapted to the digestive 
demands of a modern high-starch diets, with more pronounced postprandial 
glycemic excursions, impaired glucose tolerance and subsequent development of 
insulin resistance [32].  Consistent with this hypothesis, in one study on overweight 
and obese individuals, a high AMY1 CNV was associated with lower fasting blood 
glucose levels [77].   
 
The association between AMY1 CNV and BMI is likely to be influenced by the 
amount of starch in the diet. In a large Swedish cohort, BMI actually increased 
significantly with increasing AMY1 CNV in those with a high starch intake. In those 
individuals with the lowest AMY1 CNV, there was a strong inverse association 
between starch intake and BMI [64]. Those with high AMY1 CNV may be better 
adapted to starch digestion, and therefore could absorb a larger amount of glucose 
from the gastrointestinal tract, thereby contributing to weight-gain [64]. 
Conversely, those with low AMY1 CNV are less adapted to digest starch, leading to 
reduced glucose uptake and increased postprandial satiety (due to undigested 
starch present in the bowel) [64, 78]. High starch intake in this group may 
therefore protect against weight-gain [64]. In addition, a further study which 
compared salivary amylase activity in normal-weight and overweight participants 
found that it was significantly higher in the overweight group, although there was 
no significant correlation between salivary amylase activity and BMI [79]; this is 
contrary to what one might expect from Mandel and Breslin’s hypothesis [32]. 
However, the authors did acknowledge that other factors, including psychological 
stress and inflammatory status, could significantly affect salivary amylase levels. 
These studies suggest that the relationship between AMY1 CNV and glucose control 
is complex. 
 
To complicate our understanding of this relationship to an even greater degree, 
more recent studies suggest that AMY1 CNV may have a smaller effect on salivary 
amylase levels and activity than previously thought [21, 58, 80].  Using more 
accurate techniques to determine exact AMY1 CNV than had been used in previous 
studies [15, 25], Carpenter and colleagues showed that whilst AMY1 CNV does 
influence salivary amylase levels and activity, it was difficult to predict levels of 
17 
 
salivary amylase from AMY1 CNV alone [58]. Given that there is a correlation 
between AMY1 and AMY2 copy numbers, it would seem logical that AMY2 could also 
have an effect on salivary amylase, but the same study found no significant 
correlation between either AMY2A or AMY2B and salivary amylase production and 
activity [58]. It remains possible that haplotypic structure of the amylase gene 
region has a more predictable effect on the expression of salivary amylase and, by 
extension, pancreatic amylase. This requires more research [58].  
 
To summarize this section, the hypothesis that higher AMY1 CNV, through 
increasing salivary amylase levels and activity, improves postprandial glucose 
control and metabolic status through CPIR is supported by data from both rodent 
and human studies as outlined above. Furthermore, the effect of AMY1 CNV on 
postprandial metabolic status is likely influenced by the amount of starch in the 
diet. However, there remains some controversy in this field, with lack of 
uniformity of across all studies, including data on the role of AMY1 CNV on 
influencing salivary amylase levels. Further studies are required to elucidate the 
precise mechanisms that link AMY1 CNV with postprandial glycaemia status, 
particularly in relation to starch-content of the diet. 
 
CNV within AMY1 and obesity 
Amylase within the serum (as opposed to amylase within the saliva) is composed of 
roughly equal proportions of salivary and pancreatic isoforms [10, 14, 81, 82]. 
Overall levels of serum amylase may therefore be affected by derangements of 
either one, or both of these isoforms [81]. Low serum amylase levels (resulting 
from, for example severe chronic pancreatitis [81]), associates with metabolic 
abnormalities, Diabetes Mellitus (DM) and obesity [14, 81]. As with salivary 
amylase, levels of serum amylase correlate with CNV of AMY1 and AMY2 [10, 17, 
60, 61].  
 
A significant inverse correlation between serum amylase levels and BMI was first 
identified in 1988 [83]. Interestingly, serum amylase levels in obese participants 
increase following weight-loss. Further studies have replicated inverse correlations 
between serum amylase levels and BMI [60, 81, 84-89], impaired glucose tolerance 
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[84], insulin resistance [60, 87, 89], DM [88], waist circumference and percentage 
body fat [60, 86], and a positive correlation of serum amylase levels with high-
density lipoprotein (HDL) cholesterol [84]. Although most of these studies were on 
Asian populations, others (that have also included assessment of salivary and 
pancreatic origins for serum amylase levels) have shown comparable results in 
European populations for each amylase origin [10, 60]. 
 
In one study which examined the associations of plasma amylase activity and 
metabolic traits in a large French population, the former was found to be 
associated inversely with BMI and plasma fasting glucose levels, and directly with 
pancreatic ß-cell function [61]. Using both a Mendelian randomization analysis and 
prospective data collected after 9 years of follow-up, the authors found a causal 
negative effect of BMI on plasma amylase activity; when they used a linear 
regression model to investigate the inverse relationship, the effect of plasma 
amylase activity on change in BMI, over the follow-up period, the salivary 
component was found to significantly contribute towards increased weight loss. 
The relationship between plasma amylase activity and BMI may therefore be bi-
directional in nature, with each having a negative effect on the other [61].  
 
There may also be sex-differences in the effects of AMY1 CNV on serum amylase 
levels and BMI. In the study mentioned above, in which the relationship between 
AMY1 CNV and BMI was investigated in Finnish participants who had a history of 
severe childhood obesity, a linear regression was performed to examine the 
association between AMY1 CNV and serum amylase concentration. It was found 
that a single AMY1 copy had an effect on serum amylase that was almost three 
times greater in obese women than in obese men, suggesting that AMY1 copies may 
actually be less functional in obese men. This hypothesis is concordant with the 
other main finding of this study, that there was a significant inverse association 
between AMY1 copy number and BMI in obese females alone, and not in obese 
males or normal-weight controls [60]. 
 
It is known that insulin, delivered via a vascular portal route from the pancreatic 
islet cells directly to the acini [90], regulates pancreatic acinar function and 
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actually stimulates secretion of pancreatic amylase and other exocrine products 
[14, 90, 91]. Low serum amylase levels may therefore result from impaired insulin 
secretion [14, 81, 89] or insulin resistance [89, 92], as occurs in both obesity and 
type 2 DM [14, 89, 92]. Insulin may also influence release of salivary amylase [14, 
93,94], although this mechanism remains incompletely understood [14].  
 
A further mechanism linking serum amylase levels with BMI relates to pancreatic 
fat deposition. Fatty pancreas is associated with low serum amylase, obesity and 
markers of metabolic syndrome [95, 96]. It has been suggested that infiltration of 
the pancreas may cause damage that impairs pancreatic amylase production and 
release [88, 95]. To lend further weight to this hypothesis, fatty pancreas 
associates with fatty liver and non-alcoholic fatty liver disease (NAFLD) [96, 97], 
and an association between NAFLD and low serum amylase levels has also been 
demonstrated [81, 97, 98]. This suggests that these metabolic processes may all be 
linked [97]. In addition, it has been shown that pancreatic enzyme deficiency, as 
defined by low faecal elastase-1 levels, is found in around 50% of patients with 
type 1 diabetes mellitus and 20% of patients with type 2 diabetes mellitus [87, 99, 
100]. These findings provide further evidence of the links between the exocrine 
and endocrine functions of the pancreas and that these metabolic disease 
processes cause damage to the pancreas.  
 
As with serum amylase levels and BMI, the relationship between serum amylase 
levels and lipid profile may be bi-directional. In a study which compared the 
metabolomic signatures of female participants with lower AMY1 CNV (four or fewer 
copies) to those with higher AMY1 copy numbers (eight or more copies), the low 
AMY1 CNV group had higher serum levels of dicarboxylic fatty acids, which 
indicates up-regulation of -oxidation of fatty acids, and lower concentrations of 
several medium- and long-chain fatty acids [17]. This was indicative of more active 
uptake and oxidation of fatty acids. Levels of 2-hydroxybutyrate, which is noted to 
be a biomarker for insulin resistance [101], were also higher those with low AMY1 
CN, while serum glucose was also slightly increased.  Considered as a whole, these 
results indicated ‘a pattern of reduced cellular glucose uptake, and a consistent 
metabolic shift toward lipid exploitation’ in the women with low AMY1 CNV [17]. 
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Serum amylase may also function as a cardio-protective factor, in a similar way to 
the insulin-sensitising, anti-inflammatory and anti-atherogenic functions of 
adiponectin [85, 86, 102], and has even been shown to correlate with serum 
adiponectin in Japanese women [86, 103]. In this way, serum amylase may protect 
against the adverse metabolic features of obesity and T2D [86]. However, this 
remains speculative, and further studies are required to explore this interesting 
hypothesis further. 
 
From the above it is clear that close links exist between insulin and amylase 
release. As outlined, insulin may drive both pancreatic and salivary amylase 
production, thereby preparing the body for digestion. Salivary amylase release may 
in turn augment insulin release via CPIR in the oral cavity, and may therefore also 
augment pancreatic amylase release; as far as the authors are aware, there is as 
yet no significant evidence for any effect of pancreatic amylase on salivary 
amylase. Serum amylase may have endocrine effects on metabolism by increasing 
insulin sensitivity. These mechanisms demonstrate the existence of an ‘amylase-
insulin axis’, whereby both affect the secretion of the other. It seems likely that 
the efficacy of the protective metabolic mechanisms involving the amylase-insulin 
axis is enhanced by copy number expansion of the amylase genes (or at least the 
specific haplotype arrangement of the amylase gene region). Ectopic fat deposition 
in the pancreas (as occurs in T2D and obesity) is likely to impact negatively on the 
efficient functioning of the amylase-insulin axis. Finally, it should be noted that 
serum amylase levels are influenced by many other factors that include 
psychosocial stress [81, 104], diet [18], hydration levels [18], renal function [81, 
105], and certain medications used for T2D including dipeptidyl peptidase-4 
inhibitors and glucagon-like peptide 1 receptor agonists [81].  
 
It seems logical that the identification of a low serum amylase level has multiple 
potential clinical applications. It has been suggested that it is helpful in the 
diagnosis of chronic pancreatitis [106], but given its associations with obesity, 
impaired glucose tolerance and insulin resistance, it is feasible that it could be a 
useful tool in the recognition and monitoring of other metabolic abnormalities. The 
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measurement of serum amylase is an affordable test [86] and low levels could 
represent a biomarker of pancreatic ß-cell function [89] and be used to identify 
T2D in asymptomatic patients [86, 88]. However, these potential uses are 
problematic. First of all, the cut-off point for low serum amylase has yet to be 
clearly defined because its clinical use has so far been limited and measurement 
techniques differ [81]. Secondly, as mentioned above, serum amylase levels are 
affected by other factors: for example, its level is increased in patients with renal 
dysfunction due to reduced excretion, which means that a low amylase level in a 
patient with chronic kidney disease could appear normal [81]. Thirdly, as described 
above, the pathophysiological mechanisms that cause serum amylase to be low are 
complex and have yet to be fully explained, and further studies are needed to 
improve our understanding of them [87]. Lastly, as far as we are aware, no studies 
have yet examined whether it is useful to measure the individual pancreatic and 
salivary components of serum amylase, or just the total level. More work is 
therefore required in order to determine whether testing for low serum amylase is 
an effective means of identifying and monitoring these metabolic diseases [84, 
87]. 
 
Taken together, it is not surprising that the field of amylase research and its links 
with metabolic health remain controversial, and studies on the effects of amylase 
are inherently difficult to execute and interpret due to the complexities 
highlighted. 
 
Concluding remarks  
Amylase is an enzyme that acts primarily within the alimentary tract (mouth and 
ileum) to digest starch into disaccharides and monosaccharides that can be 
absorbed and assimilated. It is interesting that amylase is released into the serum 
from both salivary and pancreatic sources. Contrary to alimentary amylase, the 
role of serum amylase seems enigmatic, although evidence presented in this 
review reveals an amylase-insulin axis, providing integration between dietary 
signals (primarily starch content of food), and metabolic status (primarily insulin 
release). The precise mechanisms involved have yet to be elucidated, although 
amylase and insulin release appear to be influenced directly by each other. 
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Furthermore, autonomic signals may provide an ‘early warning’ for insulin release 
during and just prior to mastication of food via CPIR, and this process is likely to 
involve salivary amylase.  
 
It is plausible (although difficult to prove) that the expansion of the CNV within 
AMY1 was driven by a need for increased levels of salivary amylase, in turn driven 
by a need to digest more starch, at a specific time in early human development. As 
outlined, there appears to be association between CNV within AMY1 and both 
postprandial glycaemic control and BMI, although there is lack of uniformity of 
data among studies. Higher CNV within AMY1 appears to associate with a more 
favourable postprandial glycaemic and metabolic status. The underlying 
mechanism for this association may implicate CPIR and early insulin release 
following starch ingestion, with this response influenced by salivary amylase level, 
which in turn is influenced by CNV within AMY1. The negative association between 
CNV within AMY1 and BMI however is more difficult to explain. Obesity is 
associated with impaired beta-cell insulin release, insulin resistance and ectopic 
pancreatic fatty infiltration, each of which would be expected to impact 
negatively on pancreatic amylase release. This is one explanation for an inverse 
relationship between serum amylase levels and BMI. However, this does not explain 
the inverse relationship between CNV within AMY1 and BMI. It remains possible 
that serum amylase (in turn influenced by CNV within AMY1) have hitherto 
unknown effects on propensity for weight gain, and this should be a focus for 
future research. 
 
The potential metabolic effects of human amylase, their interactions and their 
protective properties are graphically displayed and summarised in Figure 1 and 
Table 1 respectively. 
 
Expert commentary 
The amylase field is complex. Amylase is encoded by multiple genes (divided 
broadly into salivary and pancreatic), each of which has many copies, the precise 
number being variable within the population. The copy number of each amylase 
gene likely influences its expression and the levels and activity of amylase in both 
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the alimentary tract and serum. Production and release of amylase is also likely to 
be influenced by epigenetic factors, the nature of which is incompletely 
understood. There may be age- and sex-effects on the relationship between copy 
numbers of the amylase genes and amylase levels. Amylase is itself influenced by 
other factors that include insulin, and amylase may also have both direct and 
indirect (possibly via autonomic signals) effects on insulin release. Associations 
between both amylase levels and copy number of the amylase genes versus 
postprandial metabolic status and BMI also likely pertain. These associations are 
likely affected by diet (primarily by starch content of food). Although the precise 
role of serum amylase is incompletely understood, it may play a role in the 
interplay between digestion and metabolic status through the amylase-insulin axis. 
This may explain why low serum amylase levels are associated with higher BMI and 
worse metabolic status. The link between low CNV of AMY1 and obesity however is 
more difficult to explain.  
 
More accurate characterization of the amylase gene region has revealed that 
variation in copy number may be a product of specific haplotypes, rather than a 
continuum in its own right [27, 46, 58]. Association between AMY1 CNV and BMI 
may therefore be more related to haplotypes than to copy number per se [56]. 
Whilst no study has yet found an association between AMY2 CNV and BMI, the 
correlation between the CNV of AMY1 and AMY2 implies that indirect effects of 
AMY2 CNV on BMI may exist [46]. Further large-scale studies, measuring amylase 
gene CNV and identifying specific haplotypes with accurate techniques (including 
ddPCR) are required to untangle the complex underlying relationships between the 
amylase gene region, amylase levels, metabolic status and BMI, and how these 
relationships are influenced by age and sex and other, perhaps environmental and 
dietary factors. 
 
Five-year view 
When one considers how the study of the amylase enzymes and their gene region 
has evolved over the last five years, and the complexity of the metabolic 
relationships which form the basis of this field, it seems challenging to predict 
exactly how it will progress over the next five. Nevertheless, there are several 
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promising research avenues that have yet to be explored in detail and have the 
potential to broaden our understanding, including interaction between the amylase 
gene region and gut microbiota. In a study which measured change in body fat 
percentage in mice fed a high-fat, high-sucrose diet, a SNP near the amylase gene 
region was found to be significantly associated with increased body fat growth [10, 
59, 61, 107]. This locus also associated with significant enrichment of gram-
negative Enterobacteriaceae bacteria within the gut [107], previously shown to 
predominate in the guts of overweight and obese children [10, 61, 108]. Metabolic 
and digestive effects of amylase levels (influenced by amylase gene copy number) 
may therefore be mediated via gut bacteria [59, 61]. This could be related to flux 
of undigested starch into the colon, which may be more likely in those with low 
amylase gene copy number and resulting low amylase activity, and as such 
increased fermentation by the gut microbiota with production of short chain fatty 
acids (SCFA) [109].  Although diet-induced increases of SCFA have been shown to 
have beneficial metabolic effects in relatively short-term studies mainly in animal 
models [110], long term diet-induced increases of SCFA appear to significantly 
contribute to energy intake both in humans and rodents [111, 112], with a 
contribution of up to 10 percent to energy intake even in humans [113]. Therefore, 
increased SCFA production related to non-digested starch may contribute to weight 
gain in the long term, thereby outweighing the short term metabolic benefits of 
starch-induced increased colonic fermentation.  Furthermore, increased plasma 
salivary amylase activity is associated with higher plasma levels of lactate [61], 
which is itself produced by fermentation of complex carbohydrates within the gut 
[61, 114].  A higher lactate-butyrate ratio may reduce the risk of weight gain and 
obesity through interaction with gut microbiota [61, 114]. Since alterations of gut 
microbiota may represent a potential future therapeutic strategy for insulin 
resistance and obesity [59, 115], their interactions with amylase and the metabolic 
sequelae of such interactions should be a focus for future research. 
 
Other areas for future investigation include the expression of amylase within the 
liver, increased levels of which have been associated with obesity in mice [19]. 
Expression of amylase within adipose tissue, in which AMY1 is one of the most 
highly expressed genes [10], also merits further investigation. Paracrine effects of 
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amylase within adipose tissue may shed insight into the links between AMY1 CNV 
and propensity for weight-gain. To the best of our knowledge, no study has yet 
examined the relationship between the amylase genes and other genetic loci which 
have been associated with obesity and T2D such as FTO, MC4R, CDKAL1, KCNQ1 
and KLF9 [3, 10, 51, 116, 117]: such research could help us to understand how 
these genes interact with each other to alter the risk of metabolic disease, and 
whether their mechanisms are related. Finally, the amylase-insulin axis needs 
further exploration, particularly regarding the potential for amylase to stimulate 
pancreatic insulin release (either directly or via CPIR); this research may also help 
us to understand if, and how, we can use low serum amylase levels in clinical 
practice. Looking beyond the next five years, such insight could be used to develop 
future novel therapeutic strategies for T2D, in which pancreatic insulin release is 
optimized within the postprandial phase, thereby improving overall glycaemic 
control. Such a therapy could be targeted particularly in patients known to have 
low CNV within AMY1, and low salivary and serum levels of amylase, who may 
benefit from a targeted approach to improve postprandial insulin release. It could 
also be complementary to current therapies that target (amongst other things) 
pancreatic insulin release such as the GLP-1 analogues. 
 
Obesity is the most important threat to our health, and prevention and effective 
management of weight-gain and obesity should be prioritized. Further study of the 
amylase genes and the association of their copy numbers with metabolic status and 
BMI will provide invaluable insight into the genetic determinants of metabolic 
dysfunction and BMI; and may shed light on some of the missing heritability of the 
latter. Insight into predisposition to future development of T2D and weight-gain, 
independent of specific diet and lifestyle, may also be gained from such focused 
study. In short, future focus on amylase research has much fruit to bear and will 
hold important insights into the complex interlinks between diet, digestion, 
metabolic health and BMI that in turn will provide rationale and inspiration for 
future novel therapeutic developments that may help to fight the obesity 
epidemic.     
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Key issues 
 In humans, the amylase enzyme occurs in two distinct forms: salivary 
(produced by the salivary glands) and pancreatic (produced by the exocrine 
pancreas).  These are encoded by AMY1 and AMY2 genes respectively. 
 Human salivary and pancreatic amylase genes exhibit extensive copy 
number variation.   
 Increased AMY1 copy number, which could lead to increased salivary 
amylase levels, has been linked to reduced risk of obesity and insulin 
resistance.   
 Salivary amylase may act to improve glucose tolerance and reduce the risk 
of insulin resistance by activating early ‘cephalic phase’ insulin release, 
thereby reducing post-prandial glycaemia. 
 However, copy number variation of the amylase gene region is notoriously 
difficult to measure and these findings have been questioned.  The 
relationship between the amylase gene region and salivary amylase may be 
more strongly mediated by haplotype arrangement, rather than absolute 
copy number. 
 Serum amylase is composed of roughly equal proportions of salivary and 
pancreatic isoforms, whose respective levels are influenced by AMY1 and 
AMY2 copy number and insulin.  Low serum amylase levels have been 
associated with metabolic abnormalities, Diabetes Mellitus and obesity. 
 Serum amylase may reduce the risk of metabolic abnormalities by increasing 
insulin sensitivity. 
 Further research is needed in order to further elucidate the functional 
properties of the amylase gene region, the nature of the amylase-insulin 
axis, and the way in which they may interact with the gut microbiota.  
Improving our understanding of this area could lead to future novel 
therapies for metabolic abnormalities. 
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